The two companies have formalized their desire to collaborate in a recent letter of intent, and are presently preparing the contractual details of their collaboration. They plan to primarily focus on the sourcing of cancer treatments, but are open to future expansion to other therapeutic areas as well.
Konstantinos Kardiasmenos, CEO of NextGen, said: “Beckpharma’s strength lies in identifying and acquiring promising cancer treatments through the relationships it has built with academic research institutions around the world.”